Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma

NCT01907308 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Sponsor's decision to terminate the study

Conditions

Urothelial Carcinoma

Interventions

DRUG: AMG 386
DRUG: Docetaxel

Sponsor

University of Colorado, Denver

Collaborators

[object Object]